Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	201	222	150	127	206	148
Short-Term Investments	621	759	828	632	803	351
Cash & Short-Term Investments	822	981	978	759	1,009	499
Cash Growth	-17.55%	0.31%	28.85%	-24.78%	102.20%	-31.52%
Accounts Receivable	3	11	20	38	39	745
Total Trade Receivables	3	11	20	38	39	745
Other Current Assets	19	15	18	34	19	18
Total Current Assets	844	1,007	1,016	831	1,067	1,262
Net Property, Plant & Equipment	38	40	47	51	35	32
Long-Term Investments	54	29	14	107	129	182
Other Long-Term Assets	61	63	73	106	114	116
Total Assets	997	1,139	1,150	1,095	1,345	1,592
Accounts Payable	39	42	18	17	20	10
Unearned Revenue	34	35	85	91	97	102
Other Current Liabilities	136	154	123	76	76	54
Total Current Liabilities	209	231	226	184	193	166
Long-Term Debt	100	99	48	-	-	-
Other Long-Term Liabilities	164	178	391	449	495	584
Total Long-Term Liabilities	264	277	439	449	495	584
Total Liabilities	473	508	665	633	688	750
Common Stock	2,138	2,116	1,617	1,311	1,206	1,118
Additional Paid-in Capital	2,138	2,116	1,617	1,311	1,206	1,118
Accumulated Other Comprehensive Income	-1	-	-	-	-7	-1
Retained Earnings	-1,613	-1,485	-1,132	-849	-542	-275
Shareholders' Equity	524	631	485	462	657	842
Total Liabilities & Equity	997	1,139	1,150	1,095	1,345	1,592
Total Debt	100	99	48	0	0	0
Net Cash (Debt)	722	882	930	759	1,009	499
Net Cash Growth	-18.14%	-5.16%	22.53%	-24.78%	102.20%	-30.05%
Net Cash Per Share	6.32	8.21	10.32	10.26	14.01	6.74
Book Value	524	631	485	462	657	842
Book Value Per Share	4.59	5.88	5.38	6.24	9.13	11.38
Tangible Book Value	524	631	485	462	657	842
Tangible Book Value Per Share	4.59	5.88	5.38	6.24	9.13	11.38

Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q